Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease

Trial Profile

Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eltoprazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Sponsors Amarantus Bioscience Holdings
  • Most Recent Events

    • 28 Mar 2018 According to an Amarantus Bioscience Holdings media release, in April 2017, Amarantus incorporated the wholly-owned subsidiary Elto Pharma, Inc. for the purpose of raising capital to finance the further clinical development of Eltoprazine.
    • 28 Mar 2018 According to an Amarantus Bioscience Holdings media release, the companys initial go-public effort will be focused on Elto Pharma to support this pending phase 2b trial.
    • 08 Mar 2018 According to an Elto Pharma (wholly-owned subsidiary of Amarantus Bioscience Holdings) media release, the Company is currently preparing to redesign its Phase 2b PD-LID trial into a Phase 3-enabling parallel design clinical trial as a result of the recent approval of Gocovri from Adamas Pharmaceuticals for the treatment of PD-LID.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top